Pfizer announced FDA approval of TUKYSA with trastuzumab and pertuzumab for maintenance in adults with unresectable HER2+ breast cancer, expanding its use to frontline metastatic disease after induction. The move could broaden TUKYSA's addressable market and lift near-term sales if clinicians adopt the regimen and payers reimburse. The success hinges on uptake, payer coverage, and competitive dynamics in the HER2 space.
Pfizer plans to cut about 330 jobs at its Sicily plant in Italy, per labour unions. The move underscores ongoing downsizing of Pfizer's international footprint and could affect local manufacturing capacity, though there is no stated impact on earnings guidance. Investors should monitor whether this signals broader cost-cutting or restructuring across its global operations.
The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, Valneva and Pfizer’s Lyme disease vaccine candidate. While Valneva’s shares jumped on the news, Pfizer’s stock impact remains uncertain and hinges on European approval and commercialization. The milestone de-risks the program and could unlock royalties or licensing opportunities if Europe approves the vaccine.
Pfizer posted Q2 earnings of $0.77 per share on $15.03 billion in sales, ahead of estimates for $0.69 and $14.41 billion. The results reinforce momentum in Pfizer's portfolio and could support near-term upside for PFE shares amid a broad market rally driven by tech leadership. Investors will scrutinize forward guidance and product mix updates for visibility on 2024–2025 profitability.
Pfizer reported a Q2 profit beat fueled by robust Eliquis demand, underscoring the drug as a core earnings pillar. If Eliquis sustains its growth, Pfizer could see continued profitability and potential upside to guidance in the near term. Investors will watch Eliquis dynamics and broader margin trends to gauge sustained momentum.
Pfizer reported that its oral candidate for vitiligo achieved color restoration in two late-stage trials, clearing a key clinical hurdle and paving the path to regulatory submissions. If regulators accept the data, the therapy could become a new growth driver for Pfizer, contingent on safety outcomes and labeling decisions, and may influence near-term sentiment around PFE.
